Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In what is being called the first formidable entry into the African market by a leading pharmaceutical group, Daiichi Sankyo and its Indian generic subsidiary Ranbaxy announced Dec. 22 they will jointly launch Daiichi's proprietary hypertension treatment Olvance (olmesartan) in the six countries of Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia